UPDATE: Wedbush Securities Raises PT to $105 on HeartWare International as FDA Approves HVAD
Wedbush Securities reiterated its Outperform rating on HeartWare International (NASDAQ: HTWR) and increased its price target from $101 to $105.
Wedbush Securities commented, "FDA approves HVAD for Bridge-to-Transplant (BTT). The good: sintered device and non-restrictive label. The not-as-good: Label includes DT data snapshot with stroke rate imbalance. Favorable overall and maintain expectations for HVAD to take majority share of US BTT market by 2014. … We spoke with a number of US LVAD physicians at the American Heart Association (AHA) conference earlier this month and heard a unanimous opinion that the HVAD does not have a devicespecific thrombosis issue. Moreover, those with limited or no experience using the HVAD in clinical studies appear eager to test-drive the device."
HeartWare International closed at $89.54 on Tuesday.
Latest Ratings for HTWR
|Feb 2015||Canaccord Genuity||Maintains||Buy|
|Feb 2015||Leerink Swann||Maintains||Outperform|
|Feb 2015||JP Morgan||Maintains||Overweight|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.